Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fed state Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

NCT01794364
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 13, 2026, 10:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1

NCT01811329
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Dairy fat, Dairy fat + MFGM, Palm fat, Palm fat + MFGM
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

NCT02006537
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

NCT00828724
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

NCT02039076
View directory record Official record
Conditions
Thrombocytopenia
Interventions
avatrombopag
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

NCT01149629
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

NCT04580745
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MORF-057, Placebo for MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)

NCT07119073
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

NCT01696604
View directory record Official record
Conditions
Cachexia
Interventions
GSK2849466, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

NCT02071121
View directory record Official record
Conditions
Healthy
Interventions
BIIB061, Placebo, 14C-BIIB061
Drug
Lead sponsor
Biogen
Industry
Eligibility
20 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

NCT04908995
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral tablet, Placebo oral tablet
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

NCT05082779
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
CS0159
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Malaria: Relative Bioavailability and Food Effect of DSM265

NCT03637517
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

NCT02742779
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0310, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

NCT01209117
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 WBM Capsule, GSK2248761 WBM Tablet Formulation 1, GSK2248761 WBM Tablet Formulation 2, GSK2248761 WBM Tablet Formulation 3, GSK2248761 WBM Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817 Placebo, PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00557128
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

NCT01365000
View directory record Official record
Conditions
Healthy
Interventions
NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

NCT01821079
View directory record Official record
Conditions
Healthy
Interventions
PF-05175157
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

NCT00775151
View directory record Official record
Conditions
Healthy
Interventions
amlodipine 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2008 · Synced Sep 13, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

NCT00537654
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 13, 2026, 10:03 PM EDT